Autofleet Secures $7.5 Million For Its Vehicle-as-a-Service Platform, Enabling New Business Models for Fleets and Service Providers
16.4.2020 16:00:00 EEST | Business Wire | Press release
Autofleet, a provider of AI-powered fleet optimization and vehicle-as-a-service solutions, today announced a capital raise totaling $7.5 million from a combination of Series A and seed financing. The Series A was led by MizMaa Ventures with participation from mobility-focused investors Maniv Mobility, Next Gear Ventures and Liil Ventures. The seed financing was led by Maniv Mobility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200416005178/en/
(Photo: Business Wire)
The past decade has seen incredible growth in mobility business models such as ride-hailing and on-demand delivery, providing new means of transportation for millions of consumers. But these services have also increasingly been shown to increase congestion, struggle to retain driver supply, and lack a clear path to profitability. In parallel, traditional fleets have available and professionally-maintained vehicle supply that can be leveraged to fulfill the growing demand for mobility services, using only existing fleet assets.
Autofleet offers fleet owners and operators the tools to thrive and innovate in the new mobility landscape by automating fleet management for organizations including rental car companies, car sharing operators and car manufacturers to optimize existing business models and enable the launch of new mobility services. Autofleet has already partnered with global fleets and manufacturers such as Avis Budget Group, Zipcar, Keolis and Suzuki.
Autofleet’s platform transforms the vehicle into an elastic asset so that vehicles and rides can be spun up using an API. The platform leverages AI-based demand prediction and advanced rebalancing algorithms to centrally manage the fleet, breaking the dependence on manual and local decision making processes. By minimizing downtime and allowing for algorithmic dispatch of vehicles, the platform is designed to achieve more sustainable and profitable utilization of traditional fleet assets. Autofleet also provides a Ride & Vehicle simulator to enable operators to accurately plan and de-risk potential fleet deployments without needing a single vehicle on the road.
Fleets working with Autofleet have benefitted from the platform to more efficiently manage their field operations team and re-balance car-sharing and rental vehicles to increase fleet utilization while improving customer experience. The platform is enabling other fleet partners to transition and tap into new sources of demand such as ride-hailing trips and delivery orders. Especially now, facing the challenges of COVID-19, Autofleet is equipping fleets with the ability to shift vehicle assets to meet the acute need for logistics and medical transportation by quickly launching on-demand delivery and transportation from unutilized fleet assets.
"We at MizMaa have been highly impressed by the Autofleet team and what they are building to optimize and manage fleets for new mobility services,” said Aaron Applbaum, General Partner at MizMaa Ventures. “Every player along the new mobility value chain is facing an imbalance of vehicle availability to market demand. With Autofleet's vehicle-as-a-service layer, supply becomes elastic, making these new business models sustainable."
The funds will fuel Autofleet’s expansion into more international markets, help grow its research and development team, and accelerate its work to create new opportunities for utilizing vehicle fleets.
“Autofleet is building the most adaptive and scalable solution for managing supply side constraints,” said Olaf Sakkers, General Partner at Maniv Mobility. “As a mobility focused investor, we have learnt that the supply side is the much harder portion of the equation to make work, which is why we believe Autofleet is perfectly positioned.”
“Autofleet’s mission is to provide fleet owners the tools needed to realize the full potential of asset-heavy fleets in their transition to becoming the mobility service providers of the future,” said CEO Kobi Eisenberg. “We couldn't be more excited to partner with investors that share that vision and offer unique focus and expertise in the mobility industry to accelerate our mission globally.”
About Autofleet
Autofleet provides the leading Vehicle-as-a-Service platform for fleets to optimize existing operations and to seamlessly launch new business models from existing assets. The platform leverages advanced machine-learning algorithms for demand prediction, optimized placement and matching, automated pit-stop management and in/de-fleeting, and more. For more information, please visit https://www.autofleet.io/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200416005178/en/
Contact information
Leo Traub
Antenna Group for Autofleet
autofleet@antennagroup.com
(646) 883-3562
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
